[go: up one dir, main page]

WO2018212540A3 - Composite repebody-anticancéreux protéique à capacité de pénétration cellulaire améliorée, son procédé de préparation et utilisation - Google Patents

Composite repebody-anticancéreux protéique à capacité de pénétration cellulaire améliorée, son procédé de préparation et utilisation Download PDF

Info

Publication number
WO2018212540A3
WO2018212540A3 PCT/KR2018/005526 KR2018005526W WO2018212540A3 WO 2018212540 A3 WO2018212540 A3 WO 2018212540A3 KR 2018005526 W KR2018005526 W KR 2018005526W WO 2018212540 A3 WO2018212540 A3 WO 2018212540A3
Authority
WO
WIPO (PCT)
Prior art keywords
repebody
protein drug
anticancer
composite
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/005526
Other languages
English (en)
Korean (ko)
Other versions
WO2018212540A2 (fr
Inventor
김학성
김희연
유정현
이중재
서효덕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Advanced Institute of Science and Technology KAIST
Original Assignee
Korea Advanced Institute of Science and Technology KAIST
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020170169409A external-priority patent/KR102098709B1/ko
Application filed by Korea Advanced Institute of Science and Technology KAIST filed Critical Korea Advanced Institute of Science and Technology KAIST
Publication of WO2018212540A2 publication Critical patent/WO2018212540A2/fr
Publication of WO2018212540A3 publication Critical patent/WO2018212540A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un composite dans lequel un repebody, un domaine de pénétration cellulaire et un anticancéreux protéique sont conjugués, et son procédé de préparation et, plus précisément, un composite repebody-anticancéreux protéique ayant une capacité de pénétration cellulaire améliorée, où un domaine de pénétration cellulaire et un médicament protéique ayant une activité anticancéreuse sont conjugués au repebody ou à un dérivé de protéine comprenant le repebody à titre de squelette basique, son procédé de préparation et utilisation. Le composite repebody-anticancéreux protéique à capacité de pénétration cellulaire améliorée selon la présente invention est obtenu par conjugaison du médicament protéique, capable de détruire sélectivement uniquement les cellules cancéreuses, et doué en outre d'une spécificité de substrat élevée et d'un excellente excellente capacité d'infiltration des tissus et des tumeurs conférée par le repebody et le domaine de pénétration cellulaire. Par conséquent, le composite repebody-anticancéreux protéique est utile pour détruire des cellules cibles par liaison spécifique à des protéines cibles, tout en présentant les avantages d'une efficacité supérieure comparativement au cas où le repebody est utilisé seul, ainsi que les avantages d'une production de masse à bas coût par une expression sous forme soluble chez E. coli, qui est très stable sur le plan thermodynamique, et a une excellent pouvoir d'infiltration des tissus.
PCT/KR2018/005526 2017-05-18 2018-05-15 Composite repebody-anticancéreux protéique à capacité de pénétration cellulaire améliorée, son procédé de préparation et utilisation Ceased WO2018212540A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20170061625 2017-05-18
KR10-2017-0061625 2017-05-18
KR1020170169409A KR102098709B1 (ko) 2017-05-18 2017-12-11 세포투과능이 향상된 리피바디-항암 단백질 약물 복합체, 그 제조방법 및 용도
KR10-2017-0169409 2017-12-11

Publications (2)

Publication Number Publication Date
WO2018212540A2 WO2018212540A2 (fr) 2018-11-22
WO2018212540A3 true WO2018212540A3 (fr) 2019-03-28

Family

ID=64274366

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/005526 Ceased WO2018212540A2 (fr) 2017-05-18 2018-05-15 Composite repebody-anticancéreux protéique à capacité de pénétration cellulaire améliorée, son procédé de préparation et utilisation

Country Status (1)

Country Link
WO (1) WO2018212540A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112156189B (zh) * 2020-07-15 2023-01-17 华南师范大学 一种her2+乳腺癌靶向蛋白复合纳米粒及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013129852A1 (fr) * 2012-02-27 2013-09-06 한국과학기술원 Repebody pour une nouvelle interleukine-6 et son utilisation
US20150133308A1 (en) * 2013-11-13 2015-05-14 Korea Advanced Institute Of Science And Technology Method for improving repebody containing repeat modules
KR20160015893A (ko) * 2014-08-01 2016-02-15 한국과학기술원 생체분자를 세포 내로 전달하는 폴리펩타이드 및 그 용도
KR20160069667A (ko) * 2014-12-09 2016-06-17 전남대학교산학협력단 상피성장인자 수용체를 표적으로 하는 신규 항암제
KR20160080832A (ko) * 2014-12-29 2016-07-08 주식회사 레고켐 바이오사이언스 리피바디 유도체-약물 복합체, 그 제조방법 및 용도

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013129852A1 (fr) * 2012-02-27 2013-09-06 한국과학기술원 Repebody pour une nouvelle interleukine-6 et son utilisation
US20150133308A1 (en) * 2013-11-13 2015-05-14 Korea Advanced Institute Of Science And Technology Method for improving repebody containing repeat modules
KR20160015893A (ko) * 2014-08-01 2016-02-15 한국과학기술원 생체분자를 세포 내로 전달하는 폴리펩타이드 및 그 용도
KR20160069667A (ko) * 2014-12-09 2016-06-17 전남대학교산학협력단 상피성장인자 수용체를 표적으로 하는 신규 항암제
KR20160080832A (ko) * 2014-12-29 2016-07-08 주식회사 레고켐 바이오사이언스 리피바디 유도체-약물 복합체, 그 제조방법 및 용도

Also Published As

Publication number Publication date
WO2018212540A2 (fr) 2018-11-22

Similar Documents

Publication Publication Date Title
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
PH12021551159A1 (en) Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
EP4603507A3 (fr) Composé ayant une substance d'affinité pour une protéine soluble, une partie clivable et un groupe réactif, ou un sel de celui-ci
PH12015501092A1 (en) Anti-ceacam5 antibodies and uses thereof
EP4279513A3 (fr) Agent thérapeutique induisant la cytotoxicité
EP3949969A3 (fr) Composés benzazépine, conjugués et leurs utilisations
WO2006113623A3 (fr) Elimination d'une population de cellules heterogenes ou mixtes dans des tumeurs
EP4406612A3 (fr) Conjugués anticorps-médicament anti-cd70
EP4406544A3 (fr) Système cellulaire d'administration de principe actif ciblé
WO2009105671A3 (fr) Procédés et compositions liés aux peptides et aux protéines avec des éléments c-terminaux
CA2796722C (fr) Compositions et procedes permettant l'administration selective de molecules d'oligonucleotides a des types de neurones specifiques
HK1222122A1 (zh) 选择性药物递送组合物及使用方法
WO2015095301A3 (fr) Peptides cytotoxiques et leurs conjugués
MX2022001719A (es) Formulaciones de conjugados de benzazepina y usos de las mismas.
WO2012040459A3 (fr) Peptides de ciblage de la béta-caténine et leurs utilisations
WO2015069430A3 (fr) Anticorps anti-ceacam5 humanisé et ses utilisations
WO2013170272A3 (fr) Marquage spécifique d'un site et administration ciblée de protéines pour le traitement d'un cancer
WO2015051030A3 (fr) Polypeptides stabilisés et utilisations de ces derniers
GB201001602D0 (en) Oligopeptidic compounds and uses therof
WO2012129112A3 (fr) Utilisation d'enzymes intracellulaires pour libérer des produits bioactifs liés par covalence
AU2017250507A8 (en) Methods of treatment using chlorotoxin conjugates
EP3656788A3 (fr) Variants de liaison anti-albumine sérique améliorés
EA201691053A1 (ru) Соединения к рецептору фактора роста фибробластов 3 типа (fgfr3) и способы терапии
WO2008051852A3 (fr) Adjuvant de vaccin contre le cancer à base de matière de la matrice extracellulaire
WO2018212540A3 (fr) Composite repebody-anticancéreux protéique à capacité de pénétration cellulaire améliorée, son procédé de préparation et utilisation

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18802329

Country of ref document: EP

Kind code of ref document: A2